Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Perphenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 0.98 |
| ▸ | MAPT | P10636 | 9/20 | 0.98 |
| ▸ | LMNA | P02545 | 9/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 7/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.98 |
| ▸ | HTR2A | P28223 | 5/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.98 |
| ▸ | HRH1 | P35367 | 5/20 | 0.98 |
| ▸ | DRD3 | P35462 | 5/20 | 0.98 |
| ▸ | HTR2B | P41595 | 5/20 | 0.98 |
| ▸ | HTR1A | P08908 | 5/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.98 |
| ▸ | USP2 | O75604 | 5/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perphenazine SCHEMBL145754 | 1.00 | MAPT (0.98) | MAPTLMNASMN1; SMN2NPSR1CYP2D6 | |
| Perphenazine SCHEMBL29846305 | 1.00 | MAPT (0.98) | MAPTLMNASMN1; SMN2NPSR1CYP2D6 | |
| Perphenazine SCHEMBL29461866 | 0.99 | MAPT (1.00) | MAPTLMNASMN1; SMN2NPSR1CYP2D6 | |
| Perphenazine SCHEMBL8762197 | 0.99 | MAPT (1.00) | MAPTLMNASMN1; SMN2NPSR1CYP2D6 | |
| Perphenazine SCHEMBL42125 | 0.99 | MAPT (1.00) | MAPTLMNASMN1; SMN2NPSR1CYP2D6 | |
| Perphenazine SCHEMBL29385591 | 0.99 | MAPT (1.00) | MAPTLMNASMN1; SMN2NPSR1CYP2D6 | |
| Perphenazine SCHEMBL5307579 | 0.94 | MAPT (0.91) | MAPTLMNASMN1; SMN2NPSR1CYP2D6 | |
| Perphenazine SCHEMBL28086447 | 0.94 | MAPT (0.91) | MAPTLMNASMN1; SMN2NPSR1CYP2D6 | |
| Perphenazine SCHEMBL8014634 | 0.92 | MAPT (0.88) | MAPTLMNASMN1; SMN2NPSR1CYP2D6 | |
| Perphenazine SCHEMBL28456705 | 0.92 | MAPT (0.88) | MAPTLMNASMN1; SMN2NPSR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0214735-B1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION | Euroceltique S.A. (LU) | 1991-08-28 | — | — | EP | claimed |
| US-4834965-A | Controlled release pharmaceutical composition | EUROCELTIQUE, S.A. (LU) | 1989-05-30 | — | — | US | claimed |
| EP-0214735-A1 | Controlled release pharmaceutical composition | Euroceltique S.A. (LU) | 1987-03-18 | — | — | EP | claimed |
| CN-118454647-A | Magnetic COF@MOF adsorbent, and preparation method and application thereof | 河北大学 | 2024-08-09 | — | — | CN | disclosed |
| US-20240016745-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| EP-4260847-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-18 | — | — | EP | disclosed |
| CN-111272719-B | Fluorescence detection method and application of phenothiazine drugs | 青岛农业大学 | 2022-10-14 | — | — | CN | disclosed |
| CN-113727710-A | Solid forms of echinogenesis promoter | 斯皮诺吉尼克斯公司 | 2021-11-30 | — | — | CN | disclosed |
| US-20210205172-A1 | DRUG MANAGEMENT METHOD FOR KIT FORMULATION REQUIRING DOSE ADJUSTMENT | REGIMEN KIT INC (JP) | 2021-07-08 | — | — | US | disclosed |
| EP-3838246-A1 | DRUG MANAGEMENT METHOD FOR KIT FORMULATION REQUIRING DOSE ADJUSTMENT | Regimen Kit, Inc. (JP) | 2021-06-23 | — | — | EP | disclosed |
| CN-112912141-A | Fascin binding compounds for dendritic spine production | 斯皮诺吉尼克斯公司 | 2021-06-04 | — | — | CN | disclosed |
| US-20050119160-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2005-06-02 | — | — | US | disclosed |
| US-20050112199-A1 | Therapeutic regimens for administering drug combinations | COMBINATORX, INCORPORATED | 2005-05-26 | — | — | US | disclosed |
| WO-2005027839-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | COMBINATORX, INCORPORATED | 2004-11-11 | — | — | US | disclosed |
| US-20030232809-A1 | Lipid-rich plaque inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-18 | — | — | US | disclosed |
| EP-1302470-A1 | LIPID-RICH PLAQUE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
| EP-0214735-B1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION | Euroceltique S.A. (LU) | 1991-08-28 | — | — | EP | disclosed |
| US-4834965-A | Controlled release pharmaceutical composition | EUROCELTIQUE, S.A. (LU) | 1989-05-30 | — | — | US | disclosed |
| EP-0214735-A1 | Controlled release pharmaceutical composition | Euroceltique S.A. (LU) | 1987-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232809-A1 | Lipid-rich plaque inhibitors | LDLR, NR1H2, NR1H3 | DRD2 2560/4885MAPT 4199/4885LMNA 1016/4885 |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | HLA-DRB1, TSLP, SERPINA6 | DRD2 3053/4885MAPT 2847/4885LMNA 4062/4885 |
| US-20050119160-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | DRD2 4506/4885MAPT 1899/4885LMNA 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.